Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: Case-control study

Rheumatology International

Volumn 31, Issue 2, 2011, Pages 201-208

  Van Bommel, E F H ^a   Van Tits, L J H ^b   Van Den Berg, E A ^a   Prins, J ^a   Stalenhoef, A F H ^b  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein b; Atherosclerosis; Autoantibodies; Chronic periaortitis; Oxidized low density lipoprotein

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; AUTOANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; TAMOXIFEN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHRONIC DISEASE; CHRONIC PERIAORTITIS; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INNATE IMMUNITY; LIPID ANALYSIS; MALE; PRIORITY JOURNAL;

AGED; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; AUTOANTIBODIES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RETROPERITONEAL FIBROSIS; SMOKING; TREATMENT OUTCOME;

EID: 79954447175     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1288-6     Document Type: Article

References (42)

1. Mitchinson MJ (1986) Retroperitoneal fibrosis revisited. Arch Pathol Lab Med 110:784-786 (Pubitemid 16017776)
2. Parums DV (1990) The spectrum of chronic periaortitis. Histopathology 16:423-431 (Pubitemid 20153968)
3. Parums DV, Choudhury RP, Shields SA, Davies AH (1991) Characterisation of inflammatory cells associated with 'idiopathic retroperitoneal fibrosis'. Br J Urol 67:564-568
4. Parums DV, Chadwick DR, Mitchinson MJ (1986) The localisation of immunoglobulin in chronic periaortitis. Atherosclerosis 61:117-123 (Pubitemid 16071175)
5. Parums DV, Brown DL, Mitchinson MJ (1990) Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 114:383-387 (Pubitemid 20135843)
6. Bullock N (1988) Idiopathic retroperitoneal fibrosis. BMJ 297:240-241
7. Baker LRI (2003) Auto-allergic periaortitis (idiopathic retroperitoneal fibrosis). BJU 92:663-665 (Pubitemid 37475800)
8. Meier P, Vogt B, Blanc e (2007) Rethinking the triggering inflammatory processes of chronic periaortitis. Nephron Exp Nephrol 105: e17-e23 (Pubitemid 46006573)
9. Haug ES, Skomsvoll JF, Jacobsen G, Halvorsen TB, Saether OD, Myhre HO (2003) Inflammatory aortic aneurysm is associated with increased incidence of autoimmune disease. J Vasc Surg 38:492-497 (Pubitemid 41123211)
10. Vaglio A, Corradi D, Manenti L, Ferretti S, Garini G, Buzio C (2003) Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med 114:454-462 (Pubitemid 36515107)
11. Galkina E, Ley K (2009) Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 27:165-197
12. Van Bommel EFH, van der Veer SJ, Hendriksz TR, Bleumink GS (2008) Persistent chronic periaortitis ('inflammatory aneurysm') after abdominal aortic aneurysm repair: systematic review of the literature. Vasc Med 13:293-303
13. Bommel Van, Hendriksz TR, Huiskes AW, Zeegers AG (2006) Brief communication: tamoxifen therapy for idiopathic retroperitoneal fibrosis. Ann Intern Med 144:101-106 (Pubitemid 46768228)
14. Van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49:615-625 (Pubitemid 46654499)
15. van Tits LJH, de Waart F, Hak-Lemmers HLM (2001) Effects of alfa-Tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. Free Radical Biol Med 30:1122-1129 (Pubitemid 32441837)
16. Virella G, Lopes-Virella MF (2003) Lipoprotein autoantibodies: measurement and significance. Clin Diagn Lab Immunol 10:499-505 (Pubitemid 36890428)
17. Shoenfeld Y, Wu R, Dearing LD, Matsuura e (2004) Are antioxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 110(17):2552-2558 (Pubitemid 39453000)
18. Tsimikas S, Willerson JT, Ridker PM (2006) C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 47: C19-C31
19. Van Bommel EFH, Jansen I, Hendriksz TR, Aarnoudse ALHJ (2009) Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiological presentation. Medicine 88:193-201
20. Bonanni B, Johansson H, Gandini S et al (2003) Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. J Thromb Haemost 1:2149-2152
21. De Medina P, Payre BL, Bernad J et al (2004) Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol 308:1165-1173 (Pubitemid 38263994)
22. Grainger DJ, Schofield PM (2005) Tamoxifen for the prevention of mycardial infarction in humans: preclinical and clinical evidence. Circulation 112:3018-3024 (Pubitemid 41612306)
23. Tinahones FJ, Gomez-Zumaquero JM, Garrido-Sanchez L et al (2005) Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Res 46:452-457 (Pubitemid 43109781)
24. Gomez-Zumaquero JM, Tinahones FJ, de Ramón E, Camps M, Garrido L, Soriguer FJ (2004) Association of biological markers of activity of lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies. Rheumatology 43:510-513 (Pubitemid 38489370)
25. Tsutsumi Z, Moriwaki Y, Takahashi S, Ka T, Yamamoto T (2004) Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. Clin Chim Acta 339:117-122 (Pubitemid 37547948)
26. Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, Morris CJ (1993) Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patient with rheumatoid arthritis. Ann Rheum Dis 52:677-680 (Pubitemid 23280438)
27. Dotevall A, Hulthe J, Rosengren A, Wiklund O, Wilhelmsen L (2001) Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci 101:523-531 (Pubitemid 33032997)
28. Georgiades SJ, Wu R, Thulin T, Frostegard J (2006) Antibodies of IgM subclass to phosphorycholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188:160-166 (Pubitemid 44160704)
29. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF (1999) Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48(7):1454-1458 (Pubitemid 29297310)
30. Van Tits LHJ, Himbergen TM, Lemmers HLM, de Graaf J, Stalenhoef AFH (2006) Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185:307-312
31. Van Tits LHJ, De Graaf J, Hak-Lemmers H, Bredie S, Demacker P, Holvoet P, Stalenhoef AFH (2003) Increased levels of lowdensity lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab Invest 83:13-21 (Pubitemid 36126047)
32. Swets BP, Brouwer DAJ, Cohen Tervaert JW (2001) Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol 124:163-167 (Pubitemid 32476947)
33. Heikkinen AM, Niskanen L, Ylä-Herttuala S et al (1998) Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL. Maturitas 29:155-161 (Pubitemid 28267275)
34. Bureau I, Laporte F, Favier M et al (2002) No antioxidant effect of combined HRT on LDL oxidizability and oxidative stress biomarkers in treated post-menopausal women. J Am Coll Nutr 21:333-338 (Pubitemid 34832553)
35. Hoogerbrugge N, Zillekens MC, Jansen H et al (1998) Estrogen replacement decreased the levels of antibodies against oxidized low density lipoprotein in postmenopausal women with coronary heart disease. Metabolism 47:675-680 (Pubitemid 28265170)
36. Uint L, Gebara OCE, Pinto LB et al (2003) Hormone replacement therapy increases levels of antibodies against heat shock protein 65 and certain species of oxidized low density lipoprotein. Braz J Med Biol Res 36:491-494 (Pubitemid 36592152)
37. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W (2005) Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112:651-657 (Pubitemid 41099043)
38. Hulthe J, Fagerberg B (2002) Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 22:1162-1167 (Pubitemid 34764868)
39. Nitecki SS, Hallett JW, Stanson AW, Ilstrup DM, Bower TC, Cherry KJ, Gloviczki P, Pairolero PC (1996) Inflammatory abdominal aneurysms: a case-control study. J Vasc Surg 23:860-869 (Pubitemid 26159173)
40. Frostegard J, Ruihua WU, Lemne C, Thulin T, Witzum JL, de Faires U (2003) Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci 105:615-620 (Pubitemid 37421657)
41. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J (1995) Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15:441-445
42. *03: another clue to an autoimmune origin. Arthritis Rheum 55:126-130 (Pubitemid 43235137)